Gastrointestinal Drugs Advisory Committee



June 26, 2003



1.     Appropriate patients for PHOTOFRIN PDT


a)     The diagnosis of high-grade dysplasia was confirmed by the Central Reference Laboratory in about 50% of patients with that diagnosis. Discuss what impact the inability to confirm a high-grade dysplasia diagnosis has on the use of PHOTOFRIN. Provide recommendations to ensure use of this therapy in the appropriate population.


b)     Should the diagnosis of high-grade dysplasia be confirmed by a reference laboratory of acknowledged experts before PHOTOFRIN PDT is undertaken?



2.     Efficacy


a)     Do the applicant’s data demonstrate efficacy of PHOTOFRIN PDT in complete ablation of high-grade dysplasia in Barrett’s esophagus?


b)     Is a 2-year follow-up period adequate to demonstrate cancer risk reduction in high-grade dysplasia patients treated with PHOTOFRIN PDT?


c)     How frequently should patients who have undergone PHOTOFRIN PDT be monitored by esophagoscopy?



3.     Safety:


Is the safety profile of PHOTOFRIN PDT acceptable?



4.     Follow-up


The applicant is continuing to collect patient follow-up data in the PHO BAR 02 study for an additional 3 years. PHO BAR 01 and PHO BAR 02 taken together will provide a maximum of 5 years of follow-up for patients in the 2 arms of the study. Is this adequate to demonstrate cancer risk reduction in high-grade dysplasia patients?